CN116672450A - Hpk1抑制剂在治疗干扰素相关疾病中的应用 - Google Patents

Hpk1抑制剂在治疗干扰素相关疾病中的应用 Download PDF

Info

Publication number
CN116672450A
CN116672450A CN202210168693.XA CN202210168693A CN116672450A CN 116672450 A CN116672450 A CN 116672450A CN 202210168693 A CN202210168693 A CN 202210168693A CN 116672450 A CN116672450 A CN 116672450A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
virus
alkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210168693.XA
Other languages
English (en)
Chinese (zh)
Inventor
魏文娟
彭虹
黄韬
胡显镜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ansco Suzhou Pharmaceutical Technology Co ltd
Original Assignee
Zhichong Pharmaceutical Beijing Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhichong Pharmaceutical Beijing Co ltd filed Critical Zhichong Pharmaceutical Beijing Co ltd
Priority to CN202210168693.XA priority Critical patent/CN116672450A/zh
Priority to KR1020247031682A priority patent/KR20240163080A/ko
Priority to CA3244921A priority patent/CA3244921A1/en
Priority to EP23759416.3A priority patent/EP4483880A4/en
Priority to JP2024550879A priority patent/JP2025508495A/ja
Priority to US18/841,184 priority patent/US20250161319A1/en
Priority to AU2023226510A priority patent/AU2023226510A1/en
Priority to PCT/IB2023/051675 priority patent/WO2023161844A1/zh
Publication of CN116672450A publication Critical patent/CN116672450A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202210168693.XA 2022-02-23 2022-02-23 Hpk1抑制剂在治疗干扰素相关疾病中的应用 Pending CN116672450A (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN202210168693.XA CN116672450A (zh) 2022-02-23 2022-02-23 Hpk1抑制剂在治疗干扰素相关疾病中的应用
KR1020247031682A KR20240163080A (ko) 2022-02-23 2023-02-23 인터페론 관련 질환의 치료에서 hpk1 억제제의 응용
CA3244921A CA3244921A1 (en) 2022-02-23 2023-02-23 USE OF AN HPK1 INHIBITOR IN THE TREATMENT OF INTERFERON-RELATED DISEASES
EP23759416.3A EP4483880A4 (en) 2022-02-23 2023-02-23 USE OF AN HPK1 INHIBITOR IN THE TREATMENT OF INTERFERON-RELATED DISEASES
JP2024550879A JP2025508495A (ja) 2022-02-23 2023-02-23 インターフェロン関連疾患の治療におけるｈｐｋ１阻害剤の応用
US18/841,184 US20250161319A1 (en) 2022-02-23 2023-02-23 Use of hpk1 inhibitor in treatment of interferon-related diseases
AU2023226510A AU2023226510A1 (en) 2022-02-23 2023-02-23 Use of hpk1 inhibitor in treatment of interferon-related diseases
PCT/IB2023/051675 WO2023161844A1 (zh) 2022-02-23 2023-02-23 Hpk1抑制剂在治疗干扰素相关疾病中的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210168693.XA CN116672450A (zh) 2022-02-23 2022-02-23 Hpk1抑制剂在治疗干扰素相关疾病中的应用

Publications (1)

Publication Number Publication Date
CN116672450A true CN116672450A (zh) 2023-09-01

Family

ID=87764942

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210168693.XA Pending CN116672450A (zh) 2022-02-23 2022-02-23 Hpk1抑制剂在治疗干扰素相关疾病中的应用

Country Status (8)

Country Link
US (1) US20250161319A1 (https=)
EP (1) EP4483880A4 (https=)
JP (1) JP2025508495A (https=)
KR (1) KR20240163080A (https=)
CN (1) CN116672450A (https=)
AU (1) AU2023226510A1 (https=)
CA (1) CA3244921A1 (https=)
WO (1) WO2023161844A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116514728A (zh) * 2022-01-28 2023-08-01 赛诺哈勃药业（成都）有限公司 一种喹唑啉衍生物及其用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025228828A1 (en) * 2024-04-29 2025-11-06 Merck Patent Gmbh Carboxamide compounds for the treatment and prevention of viral diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
WO2015083833A1 (ja) * 2013-12-06 2015-06-11 カルナバイオサイエンス株式会社 新規キナゾリン誘導体
EP3601259B1 (en) * 2017-03-30 2022-02-23 F. Hoffmann-La Roche AG Isoquinolines as inhibitors of hpk1
TW202019905A (zh) * 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
WO2020255022A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors
TW202116753A (zh) * 2019-07-11 2021-05-01 大陸商南京征祥醫藥有限公司 以噌啉作為hpk1的抑制劑
KR20210143131A (ko) * 2020-05-19 2021-11-26 한국화학연구원 2-아미노퀴나졸린 유도체 및 이를 포함하는 항바이러스용 조성물
CN113797202B (zh) * 2020-06-16 2024-06-28 珠海宇繁生物科技有限责任公司 Hpk1激酶抑制剂在预防和/或治疗动物的病原体感染中的应用
CN114315798B (zh) * 2020-09-29 2025-03-25 安思科(苏州)医药科技有限公司 喹唑啉类化合物及其药物组合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116514728A (zh) * 2022-01-28 2023-08-01 赛诺哈勃药业（成都）有限公司 一种喹唑啉衍生物及其用途

Also Published As

Publication number Publication date
WO2023161844A1 (zh) 2023-08-31
JP2025508495A (ja) 2025-03-26
CA3244921A1 (en) 2025-06-13
EP4483880A1 (en) 2025-01-01
EP4483880A4 (en) 2026-03-11
AU2023226510A1 (en) 2024-10-10
KR20240163080A (ko) 2024-11-18
US20250161319A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
US10851109B2 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
ES2940263T3 (es) Compuestos químicos
RU2612530C2 (ru) Производные бензимидазола, полезные при лечении респираторно-синцитиальной вирусной инфекции
US10377739B2 (en) Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
CN114761397B (zh) 用于治疗呼吸道合胞病毒(rsv)感染的苯并二氮䓬衍生物
JP7667779B2 (ja) 医薬化合物
KR20180088510A (ko) 아미드 화합물, 및 rna 및/또는 dna 함유 바이러스에 의해 유발된 질환, 및 동반 질환의 예방 및 치료제로서의 용도
CN112062800B (zh) 核苷化合物的氨基磷酸酯衍生物及其用途
CN116672450A (zh) Hpk1抑制剂在治疗干扰素相关疾病中的应用
CN114014856B (zh) 作为呼吸道合胞病毒抗病毒剂的咪唑并吡啶类衍生物
CN114907284A (zh) 一种具有抗肿瘤活性的化合物及其用途
CN118126086A (zh) 一类磷酸酯类化合物、其制备方法及应用
US20230312481A1 (en) Substituted (phthalazin-1-ylmethyl)ureas, substituted n-(phthalazin-1-ylmethyl)amides, and analogues thereof
KR20180020119A (ko) 새로운 5형포스포디에스테라아제 억제제 및 그 용도
AU2012322750A1 (en) 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d] pyrimidine derivatives, their manufacture and their use as antiviral active substances
CN112638477A (zh) 作为流感病毒复制的抑制剂的吡咯并[2,3-b]吡啶衍生物
CN118580233A (zh) 3CLpro蛋白酶抑制剂的盐酸盐晶型
CN122003417A (zh) 一种nek7抑制剂、药物组合物及其用途
HK40104934A (zh) 新型肝选择性聚腺苷酸化聚合酶抑制剂及其使用方法
WO2021031997A1 (zh) 二氢嘧啶衍生物及其用途
HK40013126A (en) Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
NZ623573B2 (en) 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d] pyrimidine derivatives, manufacture and their use as antiviral active substances

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Wei Wenjuan

Inventor after: Huang Tao

Inventor before: Wei Wenjuan

Inventor before: Peng Hong

Inventor before: Huang Tao

Inventor before: Hu Xianjing

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240531

Address after: Room 210, B1, Building 218 Xinghu Street, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone, Suzhou City, Jiangsu Province, 215000

Applicant after: Ansco (Suzhou) Pharmaceutical Technology Co.,Ltd.

Country or region after: China

Address before: Room 306, Floor 3, Building 4, Yard 5, Guoxian South Third Street, Guoxian Town, Tongzhou District, Beijing, 101109

Applicant before: Zhichong Pharmaceutical (Beijing) Co.,Ltd.

Country or region before: China

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination